Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial
Björn Dahlöf(Thermo Fisher Scientific (Sweden)), Jan Östergren(Karolinska University Hospital), Jesper Mehlsen(Frederiksberg Hospital), Markku S. Nieminen(Cornell University), Arni Kristinsson(Reykjavík University), Neil R Poulter(Imperial College London), Mark J. Caulfield(Queen Mary University of London), Sverre E. Kjeldsen(Oslo University Hospital), Rory Collins(University of Oxford), DG Beevers(Birmingham City Hospital), Gordon T. McInnes(University of Glasgow), Eoin OʼBrien(University College Dublin), Peter Sever(Imperial College London), Hans Wedel(Sahlgrenska University Hospital)
Cited by 2,917
Related Papers
Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes
|New England Journal of Medicine|2008|7.4k
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
|New England Journal of Medicine|2017|6k
Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial
|The Lancet|1998|5.8k
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol
|The Lancet|2002|5.4k
Effects of Bariatric Surgery on Mortality in Swedish Obese Subjects
|New England Journal of Medicine|2007|4.6k